Phase II trial of a 75-mg/m2 dose of doc
β
Vincent A. Miller; James R. Rigas; Prudence A. Francis; Stefan C. Grant; Katheri
π
Article
π
1995
π
John Wiley and Sons
π
English
β 493 KB
π 2 views
## Background. A prior Phase I1 study of a 100-mg/m2 dose of docetaxel conducted at the Memorial Sloan-Kettering Cancer Center (New York, NY) demonstrated a 38% response rate with grade 3 or 4 neutropenia in 76% of the patients and a grade 2 or greater rash or infusionrelated reaction in 41% and 3